Clinical Trial Update: A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients [Phase 3]

View source ↗

Summary

Phase 3 randomized, placebo-controlled trial of weekly Procrit in gastric or rectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Rectal Cancer

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Gastrointestinal Cancer, Rectal Cancer | Phase 3 | Status: TERMINATED